IMN 006
Alternative Names: IMN-006Latest Information Update: 08 Dec 2023
At a glance
- Originator Immuneel Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Clinical Phase Unknown Haematological malignancies
Most Recent Events
- 19 Sep 2023 IMN 006 is available for licensing as of 19 Sep 2023. https://immuneel.com/our-partners/
- 19 Sep 2023 Clinical trials in Haematological malignancies (Parenteral) as of September 2023 (Immuneel Therapeutics Pipeline, September 2023)